Clinically acquired resistance to MAPK inhibitor (MAPKi) therapies for melanoma cannot be fully explained by genomic mechanisms and may be accompanied by co-evolution of intra-tumoral immunity. We sought to discover non-genomic mechanisms of acquired resistance and dynamic immune compositions by a comparative, transcriptomicmethylomic analysis of patient-matched melanoma tumors biopsied before therapy and during disease progression. Transcriptomic alterations across resistant tumors were highly recurrent, in contrast to mutations, and were frequently correlated with differential methylation of tumor cell-intrinsic CpG sites. We identified in the tumor cell compartment supraphysiologic c-MET up-expression, infra-physiologic LEF1 down-expression and YAP1 signature enrichment as drivers of acquired resistance. Importantly, high intra-tumoral cytolytic T cell inflammation prior to MAPKi therapy preceded CD8 T cell deficiency/ exhaustion and loss of antigen presentation in half of disease-progressive melanomas, suggesting cross-resistance to salvage anti-PD-1/PD-L1 immunotherapy. Thus, melanoma acquires MAPKi resistance with highly dynamic and recurrent nongenomic alterations and co-evolving intra-tumoral immunity.
INTRODUCTION
Understanding how melanomas acquire resistance to BRAF inhibitors (BRAFi) via genetic alterations shown to reactivate the MAPK pathway (Nazarian et al., 2010; Shi et al., 2012a Shi et al., , 2012b Shi et al., , 2014a Shi et al., , 2014b Van Allen et al., 2014; Wagle et al., 2011) has guided the clinical development of BRAFi+MEKi combinatorial therapy. Despite superior clinical benefits, the double-drug approach commonly fails due to acquired resistance (Larkin et al., 2014; Long et al., 2014b) caused by a similar set of mutant genes responsible for acquired resistance to BRAFi monotherapy (Long et al., 2014a; Moriceau et al., 2015; Villanueva et al., 2013; Wagle et al., 2014) . These shared mutations, which include V600E BRAF amplification and single nucleotide variants (SNVs) in NRAS, KRAS, MEK1/2, PTEN, CDKN2A, and DUSP4, indicate that the reservoir of genomic diversity strongly limits the long-term efficacy of dual (i.e., BRAFi+MEKi) or likely higher-order (i.e., BRAFi+MEKi+ERKi) MAPKi therapy.
In addition to harboring heterogeneous genetic alterations in the MAPK and PI3K-PTEN-AKT core pathways, melanomas at distinct sites with acquired BRAFi resistance in any given patient display extensively branched evolution (Shi et al., 2014a (Shi et al., , 2014b . Furthermore, many on-treatment tumors re-grow without any clear genetic mechanism (Rizos et al., 2014; Shi et al., 2014b) . These observations suggested that a diverse array of melanoma sub-clones, sometimes concurrent intra-tumorally, evolve to circumvent the ''bottleneck'' of BRAFi therapy (Shi et al., 2014b) and that exome-scale dissection of acquired MAPKi resistance falls short of fully explaining clinical resistance. Earlier (Johannessen et al., 2010; Nazarian et al., 2010) studies have pointed to transcriptome-based mechanisms of acquired BRAFi resistance. Given these leads, there is a clear need for comprehensive analyses of transcriptomic and epigenetic alterations underlying acquired MAPKi resistance in patient-derived melanoma samples. Identification of highly recurrent, non-genomic mechanisms may open the door to new combinatorial therapeutic strategies.
In the current therapeutic landscape, salvage therapies for patients with disease progression on MAPKi often involve immunotherapies, e.g., inhibitors of CTLA-4, PD-1 checkpoints, or CSF-1R on tumor-associated macrophages. But it is not known whether MAPKi-resistant melanomas are distinct in their immuno-phenotypes and susceptibilities to anti-CTLA-4 or -PD-1 therapies. In fact, studies are emerging which support immune microenvironment modulation by BRAFi as a contributor to in vivo anti-tumor effects. Thus, immune evasion may contribute to acquired MAPKi resistance (Ferrari de Andrade et al., 2014; Knight et al., 2013) .
Hence, we sought a landscape perspective on the relative contributions of genomic and non-genomic mechanisms to acquired MAPKi resistance and co-evolutionary dynamics of the intra-tumoral immune microenvironment in patient-derived melanoma tissues.
RESULTS

Genetic Mechanisms of Acquired MAPKi Resistance in Melanoma
We analyzed whole-exome sequences (WESs) of serial tumor biopsies (baseline and acquired resistant tumors) and normal tissues from patients with advanced melanoma treated with MAPK inhibitor (MAPKi) regiments, which included single-drug (i.e., BRAFi) or double-drug (i.e., BRAFi+MEKi) therapies (Table  S1A) . When multiple disease-progressive or acquired MAPKiresistant tumors were obtained from patients, they were compared to the same patient-matched baseline tumors. To assess the degree to which functionally validated genetic mechanisms account for clinically acquired MAPKi resistance, we visualized the recurrence of these mutations specific to or highly enriched in single-drug and double-drug disease-progressive (DP and DD-DP, respectively) melanomas (n = 67) relative to matched baseline tumors ( Figure 1A ). These functionally validated mutations (Moriceau et al., 2015; Shi et al., 2014b) 
Landscape of Transcriptomic Alterations in Acquired MAPKi Resistance
We profiled the temporal transcriptomic alterations in 48 DP or DD-DP compared with patient-matched baseline melanoma tissues (Table S1A ) and integrated analysis ( Figure S1A ) of temporal transcriptomic with expressed exomic alterations to assess the combined recurrences of GOF and LOF gene-based events. We rank-ordered recurrences of resistance-specific alterations based on the number of resistant samples and (in cases of ties) of patients. The gene list included 855 cancer-, melanoma-, and MAPKi-resistance-, and immunotherapy-related genes (Table S1B) . Importantly, among the top 30 GOF and LOF genes, transcriptomic alterations were generally more recurrent per gene and affected more genes than exomic alterations ( Figures 1B, 1C , and S1B; Tables S1C and S1D). Notably, transcriptional up-or down-expression occurred recurrently and, respectively, in bona fide, mutated GOF (i.e., BRAF, NRAS, KRAS) and LOF (i.e., CDKN2A, DUSP4) resistance genes, with the transcriptomic events exceeding the mutational events in some cases (i.e., CDKN2A, DUSP4). Interestingly, V600E/K BRAF was subject to not only mutational alterations (copy-number gain) (eight of 16) (Shi et al., 2012b) (Figures 1A and 1B) , transcriptional up-expression (three of 16), and alternative splicing (five of 16) ( Figure 1B ), but also, in the absence of aforementioned mechanisms, mutant allele-selective expression ( Figure S1B ; Table S1E ). In total, GOF events in BRAF occurred in 16 of 48 or 33% of resistant tumors. Similarly, NRAS and KRAS GOF events (26 of 48 or 54%) were a mixture of mRNA up-expression (16 of 26), mutational activation (11 of 26), and mutant allele-specific gene amplification (two of 26) (Moriceau et al., 2015) . In contrast to BRAF where both genetic and non-genetic alterations affected the mutant gene selectively, up-expression of WT NRAS or KRAS was commonly detected in acquired MAPKi-resistant melanoma tumors and was capable of conferring MAPKi resistance to sensitive melanoma lines (Lidsky et al., 2014; Shi et al., 2014b ) ( Figure S1C ). Also, Table S1 , Figure S1 , and Data S1.
we observed statistically significant overlaps between genes that were recurrently mutated and recurrently differentially expressed (maximal recurrence capped at n = 5 resistance tumors; Table S1F ). This association was particularly strong with recurrent copy-number alterations. Non-copy-number genetic alterations tended to be differentially expressed, although the statistical significance was weaker. Of interest, four genes were recurrently mutated in a GOF manner (excluding copy-number variances [CNVs] ) in at least five resistant tumors. These genes were recurrently up-expressed and included NRAS and KRAS. Most highly recurrent GOF events ( Figure 1B ; Table S1C ) were purely transcriptomic and could involve either tumor cell-intrinsic or stromal differential gene expression. c- MET and IL-8 (Sanchez-Laorden et al., 2014) were up-expressed, respectively, in 21 of 48 or 44% and 19 of 48 or 40% of resistant tumors. Furthermore, c-FOS and MEOX2 encode tumor cell-intrinsic transcriptional factors implicated in MAPKi resistance (Johannessen et al., 2013) . Other purely transcriptomic, highly recurrent GOF events involved the macrophage markers (CD163 and CD163L1). Up-expression of other genes such as CCL8 (critical for chemotaxis of monocytes, lymphocytes, and granulocytes), CSF3R (critical for granulocyte function), and NFKBIA suggested inflammatory tumor infiltration. Thus, highly recurrent and GOF transcriptomic events may reflect evolution in both the tumor cell and immune compartments of acquired MAPKi-resistant melanoma tissues.
The majority of highly recurrent LOF gene-based events (Figure 1C ; Table S1D ) arose from transcriptomic down-expressions. These involved a gene most commonly mutated in Parkinson's disease (LRRK2); an immune response modulation gene (CTLA4); antigen presentation genes (B2M, HLA-A, HLA-B, and TAP1); Wnt signaling genes (LEF1, FZD6, WNT11, and WNT10A); and RTK genes (AXL, EGFR, ALK, NTRK2, and FGFR2) . CTLA4 may be down-expressed in both the immune and tumor cell compartments, since in three melanoma expression data sets CTLA4 expression, in contrast to PDCD1 (PD-1) expression, was less correlated with the expression of T cell genes CD3, CD4, or CD8 (Table S1G) . Also, we have observed CTLA4 down-expression in several acquired MAPKi-resistant melanoma cell lines compared to their parental counterparts (data not shown). In the tumor cell compartment, CTLA4 may be a direct therapeutic target of ipilimumab (Laurent et al., 2013) . Moreover, the finding here of frequent AXL and EGFR down-expression in acquired MAPKi-resistant melanoma contrasted with previous cell line-based observations (Girotti et al., 2013; Mü ller et al., 2014) . We therefore evaluated systematically the in vivo relevance of resistance mechanisms previously proposed based on functional studies in cell lines ( Figure 1D ). Despite the clear importance of CRAF as a convergent signaling node for various mechanisms of resistance (Moriceau et al., 2015; Nazarian et al., 2010; Shi et al., 2012b) , CRAF (RAF1) itself was not subject to a single genetic or non-genetic alteration.
Beyond assessing recurrence as evidence of selection, we systematically gauged the impact of gene expression levels (top versus bottom quartiles) on TCGA melanoma patients' 10-year survival (significance cutoff, log-rank test p % 0.05). Importantly, c-MET and CTLA4 were not only the most recurrently up-and down-expressed genes, respectively, among resistant melanomas (Figures 1B and 1C) but also genes whose expression levels portended survival significance ( Figure 1E ; Table S1H ), even after adjusting for age, tumor ulceration, and stage (c-MET: Cox HR = 2.67 for the top quartile group, p value = 0.002, 95% CI, 1.4-5.0; CTLA4: Cox HR = 2.0 for the bottom quartile group, p value = 0.024, 95% CI, 1.1-3.8). In addition to assessing the survival impacts of gene expression levels, we validated our recurrent transcriptomic GOF and LOF events using a published microarray study of an independent set of tissues (Long et al., 2014a; Rizos et al., 2014) . Again, c-MET was recurrently up-expressed in 8 of 35 (23%) MAPKi-resistant tumors from 7 of 26 (27%) patients (Table S1I) ; CTLA4 was down-expressed in 9 of 35 (26%) MAPKi-resistant tumors from 7 of 26 (27%) patients (Table S1J) .
A Common Methylomic Basis of Transcriptomic Alterations
An integrated transcriptome-methylome analysis (Figures 1B and 1C) revealed a subset of recurrent differential mRNA expression events, including those affecting c-MET, LEF1, and DUSP4, as highly correlated with differential genomic DNA (gDNA) CpG methylation (Table S1K) . Methylation levels at 6,295 of all 33,874 (18.6%) CpG clusters were significantly correlated with differential mRNA expression ( Figure 1F ; Supplemental Experimental Procedures). To estimate the scope of tumor cell-intrinsic events, we calculated the numbers of expression-correlated CpG clusters across MAPKi-resistant tumors (n = 43 pairs) and cell lines (n = 5 pairs) and found that 4,486 of 6,295 (71.2%) expression-correlated CpG clusters were found in both (Figures 1F; Figure S1D ). We then performed Gene Ontology (GO) enrichment analysis of genes annotated to overlapping expressioncorrelated CpG clusters; these genes included c-MET, LEF1, and DUSP4 ( Figure 1G ; Table S1K ). Genes with methylationcorrelated up-expression were enriched for wound healing and receptor-linked or intracellular signaling, whereas genes displaying methylation-correlated down-expression were enriched for cell adhesion and neuron differentiation ( Figure 1F ). In c-MET, three CpG clusters (C1-3) with differential methylation were negatively correlated with differential mRNA expression (Figure 1G) . The extent and significance of these correlations compared favorably with those between mRNA levels of c-MET and its positive transcriptional factors (TFs) ( Figure S1E ). In nearly all (90%) pairwise comparisons of tumors and cell lines, differential c-MET mRNA expression could be accounted for by at least one differential CpG cluster methylation (Db R 10% and FDR adjusted p % 0.05). In contrast, only 48% displayed a concordant differential expression pattern of at least one c-MET TF ( Figure S1F ). Similarly for LEF1, DUSP4, and EPHA2, differential methylation at specific CpG clusters negatively correlated with differential mRNA expression (Figures 1G, S1G, and S1H; Table S1K ).
To corroborate expression-methylation correlations, we analyzed data from 335 TCGA melanoma samples. The Pearson correlation between the absolute methylation levels at C1 and normalized mRNA expression of c-MET was À0.48 (p < 2.2 e-16), while the correlation with MITF was 0.42 (p = 2.2e-15). We also compared the top and bottom quartiles of methylation levels (b values) in the c-MET CpG clusters and their mRNA expression levels. In particular, C1 CpG hypo-methylation associated strongly (Wilcoxon rank sum test p < 2.2 e-16) with high levels of c-MET mRNA expression ( Figure S1I ; C2 CpG cluster, not covered). Similar analysis for LEF1 and DUSP4 also supported expression-methylation correlations at specific CpG clusters (Figures S1J and S1K). Overall, among 7,769 individual expression-correlated CpG sites from 6,295 CpG clusters (Figure 1F) , 4,086 CpG sites (53%) showed concordant differential mRNA expression and CpG site methylation (top versus bottom quartiles) among the TCGA melanoma tumors. Furthermore, we examined our tissue-derived data for phenotypes inferred from expression patterns of methylation-regulated genes such as c-MET, LEF1, and DUSP4 (Table S1L) . Genes whose differential expression positively correlated with that of c-MET were enriched in the GO term ''pigmentation during development''; those negatively correlated for ''cell adhesion'' and ''positive regulation of cell proliferation,'' which suggested a motile phenotype (Data S1A and S1B). On the other hand, differential expression of LEF1 and DUSP4 correlated strongly with enrichment of a mutant BRAF signature (LEF1, Pearson R = 0.62 p = 8.9e-6; DUSP4, Pearson R = 0.60 p = 1.8e-5) (Data S1C and S1D), which associated LEF1 and DUSP4 down-expression with reduced MAPK addiction. Taken together, MAPK inhibition in BRAF mutant melanoma may lead to epigenetic transcriptomic alterations with functional consequences.
We then assessed whether BRAF inhibition in melanoma cell lines would lead to temporally incremental and correlated alterations between methylation and mRNA levels in c-MET, LEF1, DUSP4, and in general. Using two human
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BRAF melanoma cell lines, we profiled the methylomes and transcriptomes of vemurafenib (BRAFi)-selected sub-populations over time, including drug-tolerant persisters (DTPs) (days of treatment), drug-tolerant proliferating persisters (DTPPs) (weeks), and single-drug resistant (SDR) sub-lines (months to years) as described (Shi et al., 2014a) . We observed in time-dependent BRAFi-selected subpopulations (relative to vehicle-treated cells) methylation decreases at c-MET's nominated CpG clusters along with mRNA increases. In contrast, methylation at nominated CpG clusters in LEF1 and DUSP4 increased, while their mRNA levels decreased with BRAFi treatment duration ( Figure 1H ; Data S1E). We also examined the temporal methylation changes at all CpG sites within all genes displaying differential expression between vehicle-treated cells versus their isogenic SDR sub-lines. Importantly, the magnitudes of methylation changes were time dependent; the directions of methylation changes were concordant with the sites' correlation scores independently derived from the aggregate analysis of the tissue and cell line pairs ( Figure 1I ; Data S1F and S1G). Thus, BRAFi treatments of cell lines led to progressive methylation-expression changes akin to observations across MAPKi-sensitive versus resistant tumors.
Highly Recurrent c-MET Up-Expression Mediates MAPKi Resistance
Because acquired MAPKi-resistant melanomas displayed highly recurrent c-MET up-expression ( Figure 1B) , we compared the absolute c-MET expression levels in three resistant and one sensitive melanoma sub-groups:
down-expression, and (4) baseline ( Figure 2A ) and observed that c-MET UP resistant-melanomas in particular displayed supra-physiologic levels of c-MET transcripts compared to the sensitive, drug-naive melanomas in both our and the validation cohorts. Additionally, the overall c-MET expression levels across the spectrum of sensitive-and resistant-melanomas correlated with single-sample enrichments of c-MET signatures generated from the TCGA Melanoma data set ( Figure 2B ; Table S2 ). Genes up-expressed (log 2 FC R 2, FDR adjusted Wilcoxon p value % 0.05) in the top quartile of c-MET expression (versus the bottom quartile) defined the c-MET_UP signature, and genes up-expressed in the bottom quartile defined the c-MET_DOWN or DN signature. Importantly, c-MET up-expression in MAPKi-resistant melanomas generally concurred with positive enrichment of the c-MET_UP TCGA signatures (and down-expression with negative enrichment) ( Figure 2C ). By combining the transcriptomic analysis of RTK genes in both discovery and validation data sets (n = 82 differential expressions), we found that another RTK EPHA2, which like c-MET has been nominated as a cancer metastasis gene, was up-expressed (n = 25) in a largely mutually exclusive manner to c-MET up-expression (n = 29) (one-sided Fisher's exact test p value = 0.031; odds ratio 0.34) ( Figure 2D ). EPHA2 up-expression among MAPKi-resistant melanomas also occurred in a supra-physiologic range ( Figure S2A ), and its topquartile expression associated significantly with worse patient survival ( Figure S2B ). Using available patient-matched FFPE samples ( Figure 2E ), we detected relative c-MET protein upexpression in disease progressive tissue sections ( Figure 2F ) using a validated antibody ( Figure S2C ) and found c-MET upexpression in MAPKi resistance to be tumor cell-intrinsic.
We then assessed the functional role of tumor cell-intrinsic, supra-physiologic c-MET up-expression using two triplets of isogenic cell lines where the drug-resistant sub-lines were (1) derived from the M229 and SKMEL28 human V600E BRAF melanoma cell lines by chronic BRAFi (vemurafenib) (single-drug resistance or SDR) or BRAFi (vemurafenib)+MEKi (selumetinib) (double-drug resistance or DDR) treatment ( Figure 3A) and (2) shown to display dramatic mRNA and protein up-expression of c-MET compared to their parental cell lines. In stark contrast to acquired MAPKi-resistant cell lines driven by genetic mechanisms such as NRAS mutations,
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BRAF amplification, and/or MEK1 mutations, acquired SDR or DDR sub-lines up-expressing c-MET was highly refractory to downstream MAPK suppression ( Figure 3A ). Despite this, stimulation of cells by HGF addition during the course of BRAFi (for parental and SDR cell lines) or BRAFi+MEKi (for DDR cell lines) treatment accelerated p-ERK recovery or reactivation only in resistant cell lines and in a manner reversible by co-treatment with an inhibitor of c-MET, crizotinib ( Figure 3B ). c-MET up-expression was accompanied by enhanced activation-associated phosphorylation (Y1234/ 1235) and p-AKT (T308, S473) induction, which could be augmented by HGF stimulation and repressed by crizotinib treatment ( Figure 3C ). These studies indicate that supra-physiologic c-MET up-expression in SDR and DDR sub-lines mediates MAPK-redundant survival signaling.
Importantly, HGF stimulation enhanced the clonogenic survival of M229 and SKMEL28 SDR and DDR sub-lines cultured with MAPK inhibitor(s) but not the parental cell lines (without MAPKi) (Figure 3D ), indicating that the growth-promoting effect of HGF depended on c-MET up-expression. Also, treatments with low concentrations of crizotinib reduced the clonogenic growth of SDR and DDR sub-lines, with or without HGF stimulation, but not the parental melanoma cell lines. Furthermore, c-MET knockdown using two independent small hairpin RNA (shRNAs) ( Figure 3E ) preferentially reduced the clonogenic growth of resistant melanoma sub-lines ( Figure 3F ). Collectively, these data argue that melanoma cells can acquire MAPKi resistance via addiction to c-MET up-expression and hyper-activity. 
Altered b-Catenin-LEF1 and YAP1 Signaling Reduces Apoptosis and Promotes MAPKi Resistance
Whereas supra-physiologic c-MET up-expression in resistant tumors correlated strongly with its down-methylation, LEF1 downexpression correlated with its up-methylation ( Figures 1C and  1G ) and resulted in infra-physiologic expression levels ( Figures  4A, 4B , and S3A). Moreover, LEF1 (and its related pathway genes, FZD6 and CCND1) down-expression concurred strongly with negative enrichment of TCGA melanoma LEF1_UP signatures ( Figure 4A ; Table S3 ), indicating downregulation of b-catenin-LEF1 transcriptional activity. Consistently, we detected robust LEF1 protein down-expression in resistant tumors using a FFPE-validated antibody ( Figures S3B and S3C ). We also detected LEF1 down-expression in a panel of SDR or DDR cell lines (versus parental cell lines) ( Figure S3D ). To understand whether b-catenin-LEF1 signal downregulation promoted MAPKi resistance, we tested whether restoration of LEF1 expression and/ or b-catenin-LEF1 signaling in these MAPKi-resistant melanoma cell lines would re-sensitize them to MAPKi. GSK3b inhibition using CHIR99021 strongly decreased p-b-catenin (Ser33/37 and Thr41) and increased total b-catenin levels in the parental cell lines (e.g., Figure S3E ); these effects of GSK3b inhibition were weaker in the SDR and DDR cell lines ( Figure S3F ), consistent with a compromised b-catenin-LEF1 pathway. Importantly, GSK3bi strongly re-sensitized SDR and DDR melanoma cell lines to BRAFi and BRAFi+MEKi, respectively, and this re-sensitization to MAPKi was augmented by LEF1 re-expression in shortterm ( Figure 4C ) and long-term ( Figure 4D ) survival assays. Hence, recurrent b-catenin-LEF1 downregulation promotes MAPKi insensitivity. (F) Western blot analysis of indicated parental (P) and isogenic resistant cell lines for levels of total and phospho-YAP1 and marker proteins in cytoplasmic (C) and nuclear (N) fractions (T, total lysate). MAPKi, 1 mM. (G) Three-day survival assays of resistant melanoma cell lines at two indicated [BRAFi] or [BRAFi+MEKi] , ± YAP1 knockdown. *p < 0.01, **p < 0.001, ***p < 0.0001, Student's t test p values, ± LEF1 overexpression (C) or shVector versus shYAP1 (G) Error bars, SEM; n = 5 per group. See also Figure S3 and Table S3. Although analysis of recurrent, differential mRNA expression can uncover key transcriptome-and methylome-based resistance genes such as c-MET and LEF1, we asked whether gene signature-based analysis would identify resistance genes with post-transcriptional mechanism. One such candidate resistance gene, YAP1, was supported by recurrent signature enrichment without necessarily its mRNA up-expression in both MAPKi-resistant tumors and cell lines ( Figure 4E ). Importantly, western blot analysis showed that these acquired MAPKi-resistant cell lines harbored increased total levels of YAP1 and phospho-YAP1, in the cytoplasmic, nuclear or both compartments, compared with levels in the untreated parental cell lines (Figure 4F) . In fact, BRAFi treatment of the M229 parental line led to an accumulation of YAP1 protein but not its mRNA level. Consistently, we showed, using a validated anti-YAP1 antibody ( Figure S3G ), that YAP1 protein was up-expressed in disease progressive melanoma tissues (despite the lack of YAP1 mRNA up-expression) compared to their baseline tissues (Figure S3H) . Notably, in SDR and DDR melanoma cell lines with positive enrichment of YAP1 signatures, YAP1 knockdown ( Figure S3I ) re-sensitized these resistant cell lines to BRAFi or BRAFi+MEKi ( Figure 4G ).
Given known intersections between the b-catenin-LEF1 and YAP1 signaling pathways in other biological contexts, we explored whether b-catenin-LEF1 downregulation and YAP1 upregulation may co-regulate resistance. Inhibition of GSK3b with overexpression of LEF1 in YAP1 signature-enriched, MAPKiresistant cell lines strongly induced apoptosis, as measured by PARP1 cleavage (cPARP1) (Figure 5A ), suggesting that b-catenin-LEF1 signaling promoted apoptotic sensitivity to MAPKi. Since BIM levels are known to modulate melanoma sensitivity to apoptotic induction, we tested whether GSK3bi treatment and restoration of LEF1 expression would promote the levels of the pro-apoptotic protein BIM. Indeed, this combination accelerated and/or augmented BIM accumulation in all acquired MAPKi-resistant cell lines tested ( Figure 5B ). Interestingly, while GSK3b inhibition and YAP1 knockdown each induced apoptosis, they together induced greater apoptosis ( Figure 5C ) in association with BIM accumulation ( Figure 5D ). Consistently, GSK3b inhibition with YAP1 knockdown resulted in the most extensive clonogenic growth suppression of acquired MAPKiresistant melanoma cell lines ( Figure 5E ). Conversely, heterologous overexpression of YAP1, beyond the endogenously upexpressed levels in these resistant cell lines, reduced apoptosis and BIM induction by GSK3b inhibition (Figures 5F and 5G) . Accordingly, exogenous YAP1 overexpression strongly rescued MAPKi-resistant melanoma cells from clonogenic growth suppression elicited by GSK3b inhibition ( Figure 5H ). Together, these results support the concept that b-catenin-LEF1 and YAP1 signaling antagonistically co-regulate the tumor cellintrinsic, apoptotic threshold of melanoma to MAPKi.
Acquiring MAPKi Resistance Can Deplete and Exhaust Intra-tumoral CD8 T Cells
Among the most recurrent gene-based transcriptomic alterations in acquired MAPKi resistant melanomas were those related to tumor-associated immune cells or inflammatory states (Figures 1B and 1C) . By quantifying changes in gene set enrichment values between resistant versus matched baseline tumors, we found that the most highly recurrent net positive enrichments were in signatures related to NF-kB signaling or inflammation (from C6 oncogenic signatures, Broad Institute), monocyte functions (C7 immune signatures), and additional immune and inflammation signatures related to, for instance, T cell function, serum response, and NF-kB signaling (C2 chemical and genetic perturbation signatures) (Data S2A-S2C). In assessing a potential relationship between monocyte function and intra-tumoral inflammation, we found that the enrichments (positive or negative) of NF-kB/inflammation and of monocyte activation signatures aligned correspondingly with each other ( Figure 6A ). Additionally, positive enrichment of NF-kB or inflammation signatures related strongly to the up-expression of a panel of M2 macrophage markers, including those among the top GOF genes such as CD163 and CD163L1 ( Figure 1B) . Thus, changes in tumor-associated macrophages likely contributed to distinct inflammatory states in melanomas with acquired MAPKi resistance.
Given that tumor-associated M2 macrophages can antagonize the recruitment and effector functions of T cells, we analyzed the relationship between macrophage-associated inflammation with expression markers of T cell abundance/function. Interestingly, we found that a subset (group B, Figure 6A ) among MAPKi-resistant melanomas with enhanced expression of macrophage-associated inflammation (groups A+B, Figure 6A ) was strongly associated with reduced expression of T cell marker/function. CSF1R and CD163 (M2 macrophage markers) expression levels displayed a highly positive correlation that was comparable to the correlation between CD8A and CD8B expression levels (Data S2D and S2E), indicating that the majority of CSF1R up-expression occurred in CD163-positive macrophage cells. Furthermore, negative enrichment of the NF-kB signature in resistant tumors was significantly associated with expression loss of tumor-associated M2 macrophage markers, CD163 or CSF1R ( Figure 6B ). The putative deficiency of tumor-associated M2 macrophages and a pausi-inflammatory tumor microenvironment marked a second subset of intratumoral T cell loss. Importantly, a similar pattern of immune recomposition was observed in the validation data set (Data S2F). Thus, the states of macrophage and T cell inflammation co-evolved with MAPKi resistance, suggesting the potential utility of CSF1R inhibitors.
We investigated further the dynamic loss of CD8 T cells in a significant subset of acquired MAPKi resistance. We observed: (1) a concurrent down-expression of CD8A, CD8B, PDCD1 (PD-1), and TNFRSF9 (4-1BB/CD137), where PDCD1 (PD-1) and TNFRSF9 (4-1BB/CD137) expression marks the melanoma tumor-reactive CD8 T cell population (Gros et al., 2014) (Table  S4) , and (2) a suppression of CD8 T cell numbers (reflected by the absolute CD8A expression values) to a level significantly below the baseline range, and (3) lower CD8A (italicized) expression values in association with down-enrichment of the NF-kB signature ( Figure 6C ; Data S2G). We could directly visualize suppression of CD8 T cell numbers using anti-CD8 (along with differential levels of macrophages using anti-CD163) immunofluorescence of fixed tissues from tumor sections adjacent to those subjected to RNA sequencing (RNA-seq) ( Figure 6D ). Given highly recurrent down-expression of antigen presentation genes (e.g., B2M, HLA-A, HLA-B, and TAP1) ( Figure 1C) , we analyzed the potential relationship in the dynamic expression of genes related to antigen presentation, dendritic cells, and CD8 T cells ( Figure 6E ). This revealed a consistent concurrence between levels of intra-tumoral antigen presentation and CD8 T cells/ function in both the discovery and validation tissue cohorts, indicating that $50% of all resistant melanoma displayed a relative loss of CD8 T cells and their function (Data S2H). This was not surprising considering a general and tight correlation between CD8A versus TAP1 or B2M expression levels among all melanomas in our cohort ( Figures 6F and 6G ), in the validation cohort ( Figure S4A) , and in the TCGA melanoma cohort ( Figure S4B) . Importantly, the subgroups of resistant melanomas with CD8A down-expression or of all melanomas with the lowest quartile of CD8A expression displayed a high ratio of EOMES/CD8A expression (where EOMES is a transcription factor related to T cell exhaustion (Twyman-Saint Victor et al., 2015) ( Figures  6H and S4C) . Reduced intra-tumoral CD8A expression was associated with increased ratios of expression in a panel of CD8 T cell exhaustion genes to CD8A (Figure 6I ), and the subgroup of resistant tumors with CD8A down-expression was strongly associated with T cell exhaustion ( Figure S4D ). Moreover, expression levels of the CD8 T cell marker (CD8A), its functional feedback (PDCD1/PD-1, CD274/PD-L1) driven by IFN-g, and its effector function (geometric average of PRF1, GZMA expressions defined as a cytolytic score (Rooney et al., 2015) were found to be clinically important, as they impacted patient survival in the TCGA melanoma data ( Figure 6J) . Lastly, the dynamic nature of intra-tumoral CD8 T cells before and during progression on MAPKi therapy was further underscored by an inverse relationship in the expression levels of these CD8 T cell marker/function genes at baseline and during disease progression ( Figures  6K and S4E ). In short, MAPKi resistance and CD8 T cell deficiency/exhaustion co-evolve frequently with downregulation of the antigen presentation machinery.
DISCUSSION
Unraveling the complexities of cancer genomics has relied heavily on the recurrence of genetic events as a sine qua non evidence for functional selection. However, when the evolution of melanoma treated with MAPK inhibitor(s) was actually sampled by serial biopsies, the genetic variants positively selected by the inhibitors were not highly recurrent and together could not explain clinical relapse comprehensively. Here, we showed that gene-and signature-based transcriptomic alterations in acquired MAPKi-resistant melanoma were highly recurrent. Transcriptomic alterations, unlike mutations, could not be attributed to tumor or stromal/immune cells without specific validations through histologic analysis of tissues and functional analysis of cell line models of acquired resistance. We highlighted specific genes (c-MET, LEF1, YAP1) and pathways subject to recurrent differential regulation in resistant tumor cells. That c-MET upand LEF1 down-expression cause acquired MAPKi resistance is reminiscent of findings that HGF stimulation and b-catenin activation can modulate innate BRAFi sensitivity (Biechele et al., 2012; Straussman et al., 2012) . Thus, determinants of innate versus acquired MAPKi resistance may converge on pathways. This is further exemplified in studies showing PI3K-AKT activation in both early and late resistance (Obenauf et al., 2015; Shi et al., 2011 Shi et al., , 2014a Shi et al., , 2014b . As YAP1 signal activation in resistant melanoma appeared post-transcriptional, its altered post-translational regulation requires additional studies. Overall, genetic and epigenetic mechanisms can account broadly for disease progression on MAPKi therapies and contribute extensively to intra-tumor/patient and inter-patient tumor heterogeneity (Figures 7A and 7B) .
For some of the gene targets of transcriptomic and functional alterations identified in MAPKi resistance (e.g., TAP1, B2M) , their baseline expression ranges in the TCGA data were shown to impact patient survival. This point is of particular importance given the highly dynamic (i.e., out of range) up-expression (c-MET, YAP1, EPHA2; Paraiso et al., 2015) or down-expression (LEF1, TAP1, B2M, CD8A, DUSP4) events occurring with the evolution of MAPKi-resistant in melanoma ( Figure 7C ). It may not be surprising to find that the expression levels of genes reflective of CD8 T cell and antigen presentation abundance and function were linked to patient survival given the relatively high mutation/neoantigen load and immunogenicity of melanoma and the clinical efficacy of PD-1 targeting in melanoma. We also presented evidence that differential CpG methylation likely underlay dynamic expression of the tumor cell-intrinsic transcriptome during the evolution of MAPKi resistance. Broadly, the selection of distinct transcriptomic-methylomic state(s) imposed by MAPK-targeting likely impacts the panoply of melanoma phenotypes or ''hallmarks'' ( Figure 7D ).
Transcriptomic analysis of temporally paired tumor biopsies revealed highly recurrent evolutionary events in the immune compartment. That half of all melanoma with acquired MAPKi resistance displayed a profound CD8 T cell deficiency and exhaustion should bear on the selection of patients for salvage immunotherapies, specifically PD-1 inhibitors, and the clinical sequencing of immune checkpoint versus MAPK inhibitors. We showed that the expression levels of PD-1, T cell effector genes, and a marker of melanoma tumor-reactive CD8 T cells, TNFRSF9 (4-1BB/CD137), tightly correlated with CD8A expression. Specifically, CD8A expression in disease progressive tumors can decrease with respect to not only the patient-matched baseline expression level but also the general baseline expression range (i.e., infra-physiologic). This distinctive expression pattern of CD8A, in both relative and absolute terms, denotes both CD8 T cell depletion and exhaustion. Finally, since high intra-tumoral CD8 T cell inflammation before therapy was correlated with a loss of intra-tumoral CD8 T cell inflammation at disease progression, studies are warranted to examine the functional contributions of immune evasion to acquired MAPKi resistance, as CD8 T cells may contribute to the anti-tumor response of BRAF inhibition in vivo (Knight et al., 2013; Mok et al., 2015) .
To anticipate cancer evolution, the iterative process of understanding acquired resistance and informing next-generation therapies should incorporate analysis of both genomic and non-genomic selection, including tumor and host-immune coevolution. The extent of non-genomic and immune evolution in acquired MAPKi resistance documented here mandates a comprehensive analysis of early tumor responses to therapies in order to understand the true influence of targeted therapies on cancer evolution.
EXPERIMENTAL PROCEDURES Analyses of Tumor Specimens
Patient-matched normal tissues and melanoma tumors (pre-treatment, during disease progression) were obtained with the approval of institutional review boards (IRBs) and patients' consents. Ninety specimens were subjected to exome, transcriptome, and methylome profiling. WES and mRNA expression profiles were performed using pair-end sequencing with read length of 2 3 100 bps (Illumina HiSeq2000), except that microarray was used for tumors from patients 10-14, whereas data for patients 11-14 were taken from a published study (Long et al., 2014a; Rizos et al., 2014) . Paired methylome profiles were generated from the Illumina Infinium Methyl450K array.
Bioinformatic Analysis
We re-analyzed WES data from previous studies (Moriceau et al., 2015; Shi et al., 2014b) and defined differential gene expression (DGE) events based on the RNA-seq (2-fold cutoff) as concordant DGE calls from at least two of three programs (Supplemental Experimental Procedures). Analysis of the microarray data (DGE cutoff at 1.5-fold) of patient 10 was performed using the Oligo R package and of the validation data set using the beadarray R package. 
(legend continued on next page)
For DGE of immune genes, we relaxed the cutoffs to 1.5-fold (RNA-seq) and 1.25-fold (microarray), as the immune compartments were smaller than the tumor cell compartments. In addition to DGE, for each baseline and DP or DD-DP sample, we tabulated the normalized gene expression levels, which were expressed in FPKM. Expressed SNVs or INDELs were defined by FPKM values R0.1. CNV-related DGE events were defined as concurrent copynumber gain and RNA up-expression (log 2 FC R 1 with q value %0.05) or copy-number loss and RNA down-expression (log 2 FC % À1, q value % 0.05). To analyze gene set enrichment of paired samples, we estimated the enrichment of a gene set based on the rank sum of fold changes of genes in the set compared to all fold changes in the sample (Wilcoxon rank-sum test; p value cutoff %0.05; median of up-or down-expression across all genes in the gene set R10%). For single-sample gene set enrichments, values were derived using the GSVA program. GO enrichments were computed using DAVID.
For each CpG site in the array, the methylation change was measured by the percentage methylation difference (Db) between baseline and resistant samples. The p values for the change were corrected for multiple hypotheses testing with false discovery rates (FDR) q values %0.05 defining differential methylation. CpG clusters were defined as a set of consecutive CpG sites whose methylation changes correlated with their nearest target gene's mRNA expression changes across all resistant samples and cell lines. Those CpG sites with Pearson R correlation coefficient (adjusted) p value %0.1 were defined as expression-correlated, and their Pearson R coefficients were defined as correlation scores. For each sample, we identified all CpG clusters with significant differential methylation (q value % 0.05, jDbj R 10%) and significant DGE (q value % 0.05, jlog 2 j FCj R 1) and assessed whether the direction of the changes of methylation and mRNA expression was consistent with the overall correlation between the CpG cluster and gene expression across all samples. Based on this, we nominated DGE events as driven by differential methylation at the expression-correlated CpG cluster(s).
Cell Culture, Inhibitors, and Constructs Cell lines were maintained in DMEM with 10% heat-inactivated FBS, 2 mmol/l glutamine in a humidified 5% CO 2 incubator. Stocks and dilutions of crizotinib (Selleck Chemicals), PLX4032 (Plexxikon), AZD6244 (Selleck Chemicals), and CHIR99021 (Tocris Bioscience) were made in DMSO. HGF (Life Technologies) was suspended in PBS. MTT and clonogenic assays were performed and quantified as described (Moriceau et al., 2015) . shc-METs were cloned using the pLL3.7-GFP vector (sequences available upon request); shYAP1s were purchased from Dharmacon (vector pLK0.1); and LEF1, YAP1, and NRAS WT or Q61R were constructed in pRRLsin-cPPT-CMV-IRES-GFP and pLVXTight-puro lentiviral vectors.
Protein Detection
Cell lysates for western blots were made in RIPA buffer (Sigma) supplemented with protease (Roche) and phosphatase (Santa Cruz Biotechnology) inhibitor cocktails. We used the NE-PER Nuclear and Cytoplasmic extraction reagents (Pierce Biotechnology) for cellular fractionation. For immunohistochemistry (IHC), after deparaffinization and rehydration, tissue sections were antigenretrieved at 95 C for 30 min. Immunostaining with anti-c-MET (Cell Signaling Technology) was performed using a streptavidin-biotin, horseradish peroxidase and DAB chromogen (Vector Laboratories). IHC with anti-YAP1 (Santa Cruz Biotechnology) and anti-LEF1 (Santa Cruz Biotechnology) was performed using alkaline phosphatase, vulcan fast red chromogen (Biocare Medical), and hematoxylin counterstain (Thermo Scientific). Immunostaining with anti-CD8 (Dako) and anti-CD163 (Abcam) was visualized by TRITC-and FITC-labeled secondary antibodies, respectively, and nuclei were counterstained by DAPI.
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